Mesoblast (OTCMKTS:MEOBF) Stock Falls 13.9% – Here’s What Happened

Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price was down 13.9% during mid-day trading on Wednesday. The company traded as low as $1.14 and last traded at $1.14. 500 shares were traded during trading, a decline of 99% from the average session volume of 54,453 shares. The stock had previously closed at $1.3240.

Mesoblast Price Performance

The business’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.63.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited is an Australia-based biotechnology company that develops allogeneic cellular medicines designed to treat serious inflammatory and immune-mediated conditions. Its technology is based primarily on mesenchymal lineage cells, which are intended to regulate immune responses, reduce inflammation and support tissue repair without requiring cells to be collected from the individual patient.

The company’s lead product, remestemcel-L, is marketed in the United States under the brand name Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

See Also

• Five stocks we like better than Mesoblast
• Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
• Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
• onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
• Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage